logo-loader
ASX:CDY

Cellmid Limited

Receive alerts
Market:
ASX
Market Cap:
$18.39 m
Price
$0.22
Change
-4.35%
52 weeks high
0.41
52 weeks low
0.17

Filter by article type

Viewing results 1-25 of 190

Health

Cellmid to receive EU patent for midkine antibody for cancer, autoimmunity and inflammation

The clinical development milestone adds value to a midkine patent portfolio open to partnering....

3 weeks, 5 days ago
Health

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited outlines key components for FY2020 growth strategy ...

on 14/8/19
Health

Cellmid subsidiary Advangen International enters into agreement with K2B Co Ltd for distribution of évolis products

Avangen is engaged in the development and sale of clinically validated anti-ageing products for skin, hair and body. ...

on 6/8/19
Health

Cellmid's Japanese shopping channel sale sets revenue record of $1.14 million

Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products. ...

on 4/7/19
Health

Cellmid MD and CEO demonstrates confidence through further on-market share purchase

Maria Halasz has recently lifted her total holding to almost 2.2 million shares through acquiring a further 12,000 shares....

on 11/6/19
Health

Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

The new CEO’s mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets....

on 28/5/19
Health

Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase

The company told Proactive Investors in February that it remained on track for record revenues in financial year 2019, targeting profitability in financial year 2020....

on 6/5/19
Health

Cellmid’s évolis Professional product range to be sold in Europe

The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews. ...

on 30/4/19
Health

Cellmid alopecia patent granted in Europe for évolis® hair therapy

Notification of the intention to grant a patent will increase the commercial value of the évolis® brand beyond sales....

on 2/4/19
Retail & consumer

Cellmid demonstrates strong operational performance with revenue up to $3.6 million in first half FY19

The company has entered the 2019 calendar year in a strong position with a focus on pursuing sales channels that are most profitable, such as Japan. ...

on 21/2/19
Health

Cellmid has significant new findings on midkine published in leading medical journal

Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function....

on 7/2/19
Health

Cellmid becomes profitable in December after achieving record quarterly sales

The company continued its sales growth trajectory while substantially reducing its debt....

on 23/1/19
Health

Cellmid driving towards profitability with anti-ageing product range

The company sells clinically validated anti-ageing products for hair, skin and body....

on 11/1/19
Health

Cellmid expecting record sales in December quarter, shares up 15%

The company sells anti-ageing products for hair, skin and body....

on 12/12/18
Health

Cellmid partners with NZ pharmacies to distribute anti-ageing products

The first commercial shipment is expected to arrive this month....

on 19/11/18
Health

Cellmid builds IP for midkine portfolio with new patents

The company's patent portfolio comprises 60 patents and applications in 13 patent families....

on 7/11/18
Health

Cellmid launches évolis® Professional products in 17 store locations across the US

Cellmid is now focused on implementing a cost-effective experiential marketing solution....

on 1/11/18
Health

Cellmid banks research and development tax incentive

Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products....

on 30/10/18
Finance

Cellmid director shows faith in life sciences company through on-market trades

Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300....

on 25/9/18
Finance

Cellmid gains new substantial shareholder as director increases his interest to 6.4%

US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million....

on 14/9/18
Health

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents....

on 13/9/18
Health

Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

Cellmid can now apply to the US FDA and European EMA for Orphan Drug Designation for CAB102....

on 12/9/18
Health

Cellmid closes share purchase plan after crossing target amount

The offer was at the same price as the recent share placement to sophisticated and institutional investors for $9 million....

on 3/9/18